Abstract
The clinical presentation at the time of diagnosis and the disease course of ulcerative colitis (UC) are heterogeneous and variable over time. In population-based epidemiological follow-up studies from the last decades, the extent of UC has shown only slight variation. At diagnosis, the initial extent is evenly distributed among proctitis, leftsided, and extensive colitis with some exceptions. The disease course may vary from a single attack to chronic symptoms that reduce the quality of life as well as lead to disease extension, colectomy or even to the development of colitisassociated colorectal cancer in some cases. Important predictive clinical factors and biomarkers of disease course have been under increasing scrutiny. Those identified may eventually lead to a more personalized, tailored therapy. In this review article, the authors summarize the available evidence on the natural history and predictive markers for evaluating the course of UC.
Keywords: Ulcerative Colitis, Natural history, UC-CRC, Predictive factors, inflammatory bowel disease, Colectomy, Azathioprine, EC-IBD, Colorectal Cancer, HLA markers, IBSEN, Primary Sclerosing Cholangitis
Current Drug Targets
Title: Natural History of Ulcerative Colitis: Current Knowledge
Volume: 12 Issue: 10
Author(s): Lajos Sandor Kiss and Peter Laszlo Lakatos
Affiliation:
Keywords: Ulcerative Colitis, Natural history, UC-CRC, Predictive factors, inflammatory bowel disease, Colectomy, Azathioprine, EC-IBD, Colorectal Cancer, HLA markers, IBSEN, Primary Sclerosing Cholangitis
Abstract: The clinical presentation at the time of diagnosis and the disease course of ulcerative colitis (UC) are heterogeneous and variable over time. In population-based epidemiological follow-up studies from the last decades, the extent of UC has shown only slight variation. At diagnosis, the initial extent is evenly distributed among proctitis, leftsided, and extensive colitis with some exceptions. The disease course may vary from a single attack to chronic symptoms that reduce the quality of life as well as lead to disease extension, colectomy or even to the development of colitisassociated colorectal cancer in some cases. Important predictive clinical factors and biomarkers of disease course have been under increasing scrutiny. Those identified may eventually lead to a more personalized, tailored therapy. In this review article, the authors summarize the available evidence on the natural history and predictive markers for evaluating the course of UC.
Export Options
About this article
Cite this article as:
Sandor Kiss Lajos and Laszlo Lakatos Peter, Natural History of Ulcerative Colitis: Current Knowledge, Current Drug Targets 2011; 12 (10) . https://dx.doi.org/10.2174/138945011796818117
DOI https://dx.doi.org/10.2174/138945011796818117 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Consumption of Cooked Navy Bean Powders Modulate the Canine Fecal and Urine Metabolome
Current Metabolomics Silymarin in the Prevention and Treatment of Liver Diseases and Primary Liver Cancer
Current Pharmaceutical Biotechnology Ceramide-Based Therapeutics for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Proteomics in the Search for Biomarkers of Animal Cancer
Current Protein & Peptide Science Targeting the Tumor Stroma in Cancer Therapy
Current Pharmaceutical Biotechnology Application of In Vivo Animal Models to Characterize the Pharmacokinetic and Pharmacodynamic Properties of Drug Candidates in Discovery Settings
Combinatorial Chemistry & High Throughput Screening Bioactive Milk Lipids
Current Nutrition & Food Science Developing the Evidence Base for Cancer Chemoprevention: Use of Meta-Analysis
Current Drug Targets Nanoparticle-based Drug Delivery Systems for Targeted Epigenetics Cancer Therapy
Current Drug Targets Molecular Mechanisms of Pancreatic Cancer Dissemination: The Role of the Chemokine System
Current Pharmaceutical Design Meet Our Co-Editor
Current Vascular Pharmacology The Role of Insulin Resistance and Hyperinsulinemia in Cancer Causation
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Assessment of Nutritional Status in Cancer – The Relationship Between Body Composition and Pharmacokinetics
Anti-Cancer Agents in Medicinal Chemistry New Anti-Cancer Strategies in Testicular Germ Cell Tumors
Recent Patents on Anti-Cancer Drug Discovery Review: New Anti-Cytokines for IBD: What is in the Pipeline?
Current Drug Targets Anti-Inflammatory and Anti-Neoplastic Actions of Resveratrol
Current Nutrition & Food Science Targeting Cancer Stem Cells with Natural Products
Current Drug Targets Carcinoembryonic Antigen as a Target to Induce Anti-Tumor Immune Responses
Current Cancer Drug Targets Interactions Between Probiotic Dairy Propionibacteria and the Intestinal Epithelium
Current Immunology Reviews (Discontinued) Hsp70 Protein Complexes as Drug Targets
Current Pharmaceutical Design